CD26 IS A POTENTIAL THERAPEUTIC TARGET BY HUMANIZED MONOCLONAL ANTIBODY IN MULTIPLE MYELOMA

EHA Library, Hiroko Nishida, 214971

DNA REPAIR PROCESSES TARGET TRANSCRIBED REGION IN MULTIPLE MYELOMA

EHA Library, Nikhil Munshi, 214972

EFFECT OF DARATUMUMAB ON NORMAL PLASMA CELLS, POLYCLONAL IMMUNOGLOBULINS AND VACCINATION RESPONSES IN EXTENSIVELY PRETREATED MYELOMA PATIENTS

EHA Library, Kristine Frerichs, 214973

STUDY OF PLASMA CELL TRASCRIPTOME IN SMOLDERING MYELOMA PATIENTS IN RELATIONSHIP TO PROGRESSION TO ACTIVE MULTIPLE MYELOMA.

EHA Library, Paola Storti, 214974

LONGITUDINAL CHROMOSOMAL ABNORMALITIES ANALYSIS IN MULTIPLE MYELOMA DISEASE PROGRESSION REVEALS CLONAL EVOLUTION AFTER THERAPY.

EHA Library, Stefania Oliva, 214975

MYTYPE TARGETED NEXT GENERATION SEQUENCING ASSAY FOR DETECTION OF IGH TRANSLOCATIONS AND COPY NUMBER ALTERATIONS IN MULTIPLE MYELOMA

EHA Library, Malin Hultcrantz, 214976

RAPID AND SCALABLE GENOME-WIDE PROFILING OF CLINICALLY RELEVANT GENETIC ABERRATIONS IN MULTIPLE MYELOMA

EHA Library, Donat Alpar, 214977

INDUCTION OF STRUCTURAL AND FUNCTIONAL EFFECTS ON MYELOMA CELLS AFTER DARATUMUMAB TREATMENT

EHA Library, Angelo Corso Faini, 214978

RNA-SEQ BASED RISK STRATIFICATION IN MULTIPLE MYELOMA PATIENTS VALIDATES SKY92 AS A HIGH RISK MARKER IN THE COMMPASS TRIAL

EHA Library, Rowan Kuiper, 214979

MDSCS CONTRIBUTE TO CANCER STEM CELLS ACCUMULATION VIA PIRNA 823 UPREGULATION AND DE NOVO DNA METHYLATION IN MULTIPLE MYELOMA

EHA Library, Lisha Ai, 214980

MESENCHYMAL STROMAL CELL SIALYATION ENHANCES IMMUNE SUPPRESSION: IMPLICATIONS IN MULTIPLE MYELOMA

EHA Library, Kevin Lynch, 214981

LOW-PASS SEQUENCING OF PLASMA CELL DNA AND OF CIRCULATING CELL-FREE DNA FOR THE DETECTION OF COPY NUMBER ABERRATIONS AND EARLY RESPONSE MONITORING IN MULTIPLE MYELOMA

EHA Library, Barbara Dewaele, 214982

RNA-SEQ ANALYSIS UNRAVELS SPECIFIC LONG NON-CODING RNA TRANSCRIPTIONAL FINGERPRINTS IN MULTIPLE MYELOMA SUBTYPES

EHA Library, Elisa Taiana, 214983

COMBINATION TARGETING OF SIALYLATION AND THE PROTEASOME INHIBITS TUMOR GROWTH AND INCREASES SURVIVAL IN A HUMANIZED MOUSE MULTIPLE MYELOMA MODEL

EHA Library, Michaela Reagan, 214984

ACTIVATION OF NFAT (NUCLEAR FACTOR OF ACTIVATED T CELLS) SIGNALING AND INDUCTION OF AUTOPHAGY CONFER BORTEZOMIB RESITSTANCE IN MULTIPLE MYELOMA

EHA Library, Margaret Heung-Ling Ng, 214985

THE CONICAL AGAROSE MICROWELL ARRAY (CAMA) ENABLES 3D LONG-TERM CULTIVATION OF PRIMARY SAMPLES AND ENHANCED HIGH THROUGHPUT SCREENING FOR RATIONAL EPIGENTIC/ANTIBODY COMBINATION IN MULTIPLE MYELOMA

EHA Library, Stefan Müller, 214986

ENHANCED CYTOTOXICITY OF MULTIPLE MYELOMA CELLS USING DARATUMUMAB IN COMBINATION WITH NK CELLS ENGINEERED TO EXPRESS HIGH-AFFINITY CD16 (F158V)

EHA Library, Michael O'Dwyer, 214987

IMMUNOLOGICAL PROFILING BY MASS CYTOMETRY REVEALS THAT TIM3 EXPRESSION IS REDUCED ON NK CELL SUBSETS IN NEWLY DIAGNOSED MYELOMA AND IS ASSOCIATED WITH LOSS OF NK FUNCTION AND DECREASED SURVIVAL

EHA Library, Frances Seymour, 214988

AUTOLOGOUS STEM CELL TRANSPLANTATION AS A MODEL FOR ACCELERATED T-CELL AGING

EHA Library, Fabienne Lucas, 214989

GENE EXPRESSION PROFILING OF PROSPECTIVE SERIES IN PRIMARY PLASMA CELL LEUKEMIA REVEALED GENE SIGNATURE ASSOCIATED WITH SURVIVAL

EHA Library, Marie naudot, 214990

MDSCS PROMOTED TUMORIGENESIS OF MULTIPLE MYELOMA BOTH IN VITRO AND IN VIVO.

EHA Library, Lisha Ai, 214991

TARGETING THE INTERACTION OF MULTIPLE MYELOMA AND THE BONE MARROW MICROENVIRONMENT THROUGH NOVEL SMALL MOLECULES DIRECTED TO NOTCH PATHWAY

EHA Library, Maria Teresa Palano, 214992

EXPRESSION LEVELS OF THE THREE GENES CRBN, IKZF1, AND IKZF3 IN PRIMARY MULTIPLE MYELOMA CELLS AT PRE- AND POST- LENALIDOMIDE TREATMENT

EHA Library, Shiori kinoshita, 214993

MYC INVOLVES MULTIPLE MYELOMA PROGRESSION BY ATTENUATING TUMOR SUPPRESSIVE FUNCTION OF TP53-MICRO RNA 34 AXIS

EHA Library, Yuki Murakami, 214994

PREVENTING AND REPAIRING MYELOMA BONE DISEASE BY COMBINING CONVENTIONAL ANTI-RESORPTIVE TREATMENT WITH A NOVEL BONE ANABOLIC TREATMENT

EHA Library, Andrew Chantry, 214995

TRYPTOPHAN SHORTAGE DUE TO IDO-1 EXPRESSED BY HIGH-DENSITY NEUTROPHILS INDUCE IMMUNE-SUPPRESSION AND PLASMA CELL FITNESS IN MULTIPLE MYELOMA

EHA Library, Alessandra Romano, 214996

CHARACTERIZATION OF ST3GAL6-AS1, A NOVEL LNCRNA DEREGULATED IN MULTIPLE MYELOMA

EHA Library, Cristina Vinci, 214997

MULTIPLE MYELOMA RELATED ANGIOGENESIS: ROLE OF NOTCH-JAG AXIS IN MODULATING ENDOTHELIAL CELLS BEHAVIOR

EHA Library, Maria Teresa Palano, 214998

ADIPORON, THE FIRST ORAL ADIPONECTIN RECEPTOR AGONIST, INHIBITS THE PROLIFERATION OF MYELOMA CELLS VIA THE AMPK / MTOR /AUTOPHAGY SIGNALING PATHWAY

EHA Library, Shujuan Wang, 214999

CLINICAL RELEVANCE OF LONG NON CODING RNA IN MULTIPLE MYELOMA: RETROSPECTIVE MONOCENTRIC STUDY

EHA Library, valeria ferla, 215000

DRUG SENSITIVITY SCREENING IN MULTIPLE MYELOMA (MM) FOR PRECISION CANCER THERAPY

EHA Library, Deepak balaji Thimiri Govinda Raj, 215001

ASSESSMENT OF SELECTED TOLL-LIKE RECEPTORS EXPRESSION ONT AND B LYMPHOCYTES IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Ewelina Grywalska, 215002

DISCOVERY BLOOD PLASMA PROTEOMICS IN ELUCIDATING BIOMARKERS TO DISTINGUISH ONSET OF LETHAL MULTIPLE MYELOMA IN PREMALIGNANT MGUS

EHA Library, Luz Yurany Moreno Rueda, 215003

VARIABLES PREDICTIVE OF POOR PROGNOSIS IN PATIENTS WITH MAYO STAGE 1 SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

EHA Library, Faye Sharpley, 215004

SINGLE AGENT CARFILZOMIB PROLONGS PFS FOLLOWING TRIPLET THERAPY WITH CYCLOPHOSPHAMIDE & DEXAMETHASONE FOR FIRST RELAPSE/PRIMARY REFRACTORY MULTIPLE MYELOMA: PHASE 2 MUKFIVE STUDY, SECOND ANALYSIS

EHA Library, Kwee Yong, 215005

SUBCUTANEOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: PART 2 UPDATE OF THE OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)

EHA Library, Jesús San Miguel, 215006

LEVOFLOXACIN PROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA REDUCES FEBRILE EPISODES AND DEATH WITHOUT INCREASING HEALTHCARE ASSOCIATED INFECTIONS: RESULTS FROM THE TEAMM TRIAL

EHA Library, Stella Bowcock, 215007

PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Luciano J. Costa, 215008

A NOVEL RISK-STRATIFICATION ALGORITHM FOR RELAPSED MULTIPLE MYELOMA (RMM): ASSESSMENT OF PERFORMANCE AND VALIDATION USING REAL-WORLD PATIENT DATA FROM FRANCE, GERMANY AND THE UNITED KINGDOM

EHA Library, Roman Hájek, 215009

CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)

EHA Library, Francesca Gay, 215010

CARFILZOMIB AND DEXAMETHASONE (KD56) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED OVERALL SURVIVAL (OS), SAFETY, AND SUBGROUP ANALYSIS OF ENDEAVOR

EHA Library, Robert Orlowski, 215011

MAINTENANCE AFTER LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE INDUCTION AND TRANSPLANT IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND HIGH-RISK CYTOGENETICS: AN ENHANCED MEDICAL RECORD ANALYSIS

EHA Library, Rafael Fonseca, 215012

EUROPEAN POST-APPROVAL SAFETY STUDY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SAFETY IN PATIENTS TREATED WITH POMALIDOMIDE IN A REAL-WORLD SETTING

EHA Library, Martin Schmidt-Hieber, 215013

IMPACT OF PRIOR MALIGNANCIES ON THE DEVELOPMENT OF SUBSEQUENT MALIGNANCIES AND SURVIVAL IN MULTIPLE MYELOMA: A NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS

EHA Library, Mirian Brink, 215014

A PHASE IB STUDY OF ATEZOLIZUMAB (ATEZO) ALONE OR IN COMBINATION WITH LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)

EHA Library, Hearn Cho, 215015

TIME TO PLATEAU AS A PREDICTOR OF SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Patrick Mellors, 215016

SAFETY AND EFFICACY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IMMEDIATELY FOLLOWING LENALIDOMIDE-BASED TREATMENT FAILURE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, David S. Siegel, 215017

PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB

EHA Library, Akihiro Kitadate, 215018

UPDATED RESULTS OF A PHASE II STUDY WITH CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS.

EHA Library, Alessandra Larocca, 215019

DEVELOPMENT OF A PREDICTIVE MODEL OF MULTIPLE MYELOMA (MM) PATIENT OUTCOMES BASED ON TREATMENT (TX) SEQUENCING USING DATA FROM THE CONNECT® MM PATIENT REGISTRY

EHA Library, Sundar Jagannath, 215020

EXTERNAL VALIDATION OF THE MULTIPLE MYELOMA (MM) RISK-STRATIFICATION ALGORITHM IN A REAL-WORLD GREEK DATA SET

EHA Library, Evangelos Terpos, 215021

RANDOMIZED PHASE II STUDY TO OPTIMIZE MELPHALAN, PREDNISOLONE AND BORTEZOMIB (MPB) IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1105)

EHA Library, Dai Maruyama, 215022

REAL-WORLD TREATMENT PATTERNS AND PROGRESSION-FREE SURVIVAL (PFS) AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING POMALIDOMIDE-BASED REGIMENS

EHA Library, Ravi Vij, 215023

TIME TO FIRST ONSET OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) OF INTEREST: A POST-HOC ANALYSIS FROM ASPIRE AND ENDEAVOR TRIALS

EHA Library, Maria Victoria Mateos, 215024

SMOLDERING MYELOMA AFTER IMWG UPDATE: FACTORS PREDICTIVE OF EVOLUTION, ROLE OF ADVANCED IMAGING AND OF CLINICAL JUDGEMENT. A REAL-LIFE RETROSPECTIVE EXPERIENCE

EHA Library, AM Morelli, 215025

SAFETY OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH LENALIDOMIDE FOR ≤ 24 MONTHS VS > 24 MONTHS IN A EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS)

EHA Library, Gianpietro Semenzato, 215026

CLINICAL CHARACTERISTICS AND OUTCOMES OF OLIGOSECRETORY AND NON-SECRETORY MULTIPLE MYELOMA

EHA Library, Efstathios Kastritis, 215027

SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN INDEPENDENTLY PREDICTS FOR RENAL RESPONSE IN MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT

EHA Library, Efstathios Kastritis, 215028

DARATUMUMAB, CARFILZOMIB, AND DEXAMETHASONE (D-KD) IN LENALIDOMIDE-REFRACTORY PATIENTS WITH RELAPSED MULTIPLE MYELOMA (MM): SUBGROUP ANALYSIS OF MMY1001

EHA Library, Philippe Moreau, 215029

LONG-TERM RESULTS FROM THE HOVON-50 STUDY: IMPROVED SURVIVAL WITH THALIDOMIDE BEFORE AND AFTER TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Niels van de, 215030

THE HORIZON STUDY: A PRELIMINARY REPORT ON EFFICACY AND SAFETY OF MELFLUFEN IN LATE STAGE RELAPSED-REFRACTORY MYELOMA (RRMM) PATIENTS REFRACTORY TO POMALIDOMIDE AND/OR DARATUMUMAB

EHA Library, Maria Victoria Mateos, 215031

PHASE I-B STUDY OF ISATUXIMAB + CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Thomas Martin, 215032

IMPACT OF BASELINE RENAL FUNCTION ON EFFICACY AND SAFETY OF DARATUMUMAB PLUS BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANTATION (ALCYONE)

EHA Library, Michele Cavo, 215033

UPDATE OF THE PHASE 2 STUDY OF CARFILZOMIB, THALIDOMIDE, AND LOW-DOSE DEXAMETHASONE AS INDUCTION/CONSOLIDATION IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA, CARTHADEX TRIAL

EHA Library, Ruth Wester, 215034

CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED PATIENTS WITH AL AMYLOIDOSIS WITH “NON-MEASURABLE” FREE LIGHT CHAINS: PROGNOSTIC IMPLICATIONS AND RESPONSE EVALUATION

EHA Library, Efstathios Kastritis, 215035

SELINEXOR COMBINED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE (SPD) IN A RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION

EHA Library, Christine Chen, 215036

ABSENCE OF BONE DISEASE IS AN INDEPENDENT FAVORABLE PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN SYMPTOMATIC MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS

EHA Library, Eirini Katodritou, 215037

CORRELATION OF 11C-METHIONINE-PET AND FDG-PET IN MULTIPLE MYELOMA WITH MRD ASSESSMENT BY FLOWCYTOMETRY.

EHA Library, MARIA MARCOS JUBILAR, 215038

TRANSLOCATION (14;16) POSITIVE MULTIPLE MYELOMA PATIENTS: CLINICAL FEATURES AND SURVIVAL OUTCOMES OF A HIGH-RISK POPULATION.

EHA Library, Roberto Mina, 215039

THE SWEDISH MYELOMA REGISTRY: INCREASED SURVIVAL OVER TIME IN PATIENTS 66-80 YEARS OLD, DIAGNOSED 2008-2016

EHA Library, Cecilie Hveding Blimark, 215040

18F-FDG PET/CT AT DIAGNOSIS IS USEFUL FOR DETERMINING THE SURVIVAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA CLASSIFIED AS STAGE II WITH THE REVISED INTERNATIONAL STAGING SYSTEM

EHA Library, Sung-Hoon Jung, 215041

HAEMATOLOGICAL DIAGNOSIS AND MANAGEMENT IN MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: SINGLE CENTRE EXPERIENCE

EHA Library, Ethan Troy-Barnes, 215042

IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA – DATA FROM THE CZECH REGISTRY OF MONOCLONAL GAMMOPATHIES

EHA Library, Jiri Minarik, 215043

ALLOGRAFT IN MULTIPLE MYELOMA: EXPERIENCE OF MULTIPLE MYELOMA GIMEMA LAZIO GROUP

EHA Library, Federico Vozella, 215044

CAN STANDARDISATION BE ACHIEVED? ASSESSMENT OF PLASMA CELL MYELOMA MINIMAL RESIDUAL DISEASE TESTING BY FLOW CYTOMETRY: AN INTERNATIONAL INTER-LABORATORY STUDY

EHA Library, Stuart Scott, 215045

MP0250 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: FIRST SAFETY AND EARLY EFFICACY ANALYSIS OF MP0250-CP201

EHA Library, Monika Szarejko, 215046

STATIN USE IMPROVES MYELOMA-SPECIFIC SURVIVAL AND IS SAFE TO USE IN LYMPHOMA: A POPULATION-BASED STUDY OF 20,464 PATIENTS WITH LYMPHOID MALIGNANCIES DIAGNOSED IN SWEDEN 2007-2013

EHA Library, Elsa Brånvall, 215047

A PROSPECTIVE ANALYSIS ON THE FREQUENCY AND PREDICTIVE VALUE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY FLOW CYTOMETRY AND PET-CT IMAGING AMONG MYELOMA PATIENTS ON/OFF MAINTENANCE

EHA Library, MERAL BEKSAC, 215048

EARLY RELAPSE IS A POWERFUL INDEPENDENT NEGATIVE PREDICTOR FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS

EHA Library, Eirini Katodritou, 215049

SENSIVITY AND CLINICAL VALUE OF POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY AND WHOLE BODY MAGNETIC RESONANCE IMAGING TO ASSESS BONE DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA.

EHA Library, Elena Fernández Poveda, 215050

PHARMACOLOGIC TARGETING OF NEOPLASTIC STEM CELLS IN HUMAN MAST CELL LEUKEMIA

EHA Library, Gregor Eisenwort, 215051

THE PHENOTYPIC PROFILE OF ACUTE MYELOID LEUKEMIA SECONDARY TO CHRONIC MYELOPROLIFERATIVE NEOPLASMS: RESULTS OF A MULTI-CENTER STUDY

EHA Library, Francesco Mannelli, 215052

POTENT ACTIVITY OF AZACITIDINE ON LEUKEMIA-INITIATING CELLS IN A XENOGRAFT MODEL OF JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Miriam Erlacher, 215053

MUTATIONAL MECHANISMS OF EZH2 INACTIVATION IN MYELOID NEOPLASMS

EHA Library, Andrew Chase, 215054

MUTANT CALRETICULINS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM RETAIN IN-VITRO CHAPERONE ACTIVITY

EHA Library, Anita Roy, 215055

SDF1 ΑLPHA-INDUCED CHEMOTAXIS OF JAK2-V617F POSITIVE CELLS IS DEPENDENT ON BRUTON'S TYROSINE KINASE AND PHOSPHOLIPASE C GAMMA 1

EHA Library, Subbaiah chary Nimmagadda, 215056

HDAC INHIBITION BY VALPROIC ACID DECREASES JAK2V617F LEVELS IN MYELOPROLIFERATIVE NEOPLASMS VIA UP-REGULATION OF MIR-101, IN VIVO AND IN VITRO

EHA Library, Elisabetta De Marinis, 215057

RESULTS FROM 48-WEEK FOLLOW-UP OF THE EXPAND STUDY: A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND LOW PLATELET COUNTS (50-99 × 10^9/L) AT BASELINE

EHA Library, Peter te Boekhorst, 215058

AVAPRITINIB (BLU-285), A SELECTIVE KIT INHIBITOR, IS ASSOCIATED WITH HIGH RESPONSE RATE AND TOLERABLE SAFETY PROFILE IN ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): RESULTS OF A PHASE 1 STUDY

EHA Library, Maureen Conlan, 215059

DURABILITY OF SPLEEN RESPONSE MAY AFFECT OUTCOME OF RUXOLITINIB-TREATED PATIENTS WITH MYELOFIBROSIS: RESULTS FROM A MULTICENTRE STUDY ON 284 PATIENTS

EHA Library, Francesca Palandri, 215060

PREDICTORS OF RESPONSE TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 215061

HIGH RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AFTER TERMINATION OF ANTICOAGULATION

EHA Library, Kai Wille, 215062

RESULTS FROM ONGOING PHASE 1/2 TRIAL OF SL-401 IN PATIENTS WITH INTERMEDIATE OR HIGH RISK RELAPSED/REFRACTORY MYELOFIBROSIS

EHA Library, Naveen Pemmaraju, 215063

BONE MARROW MORPHOLOGY IN PATIENTS WITH POLYCYTHEMIA VERA RESISTANT TO FIRST AND SECOND LINE THERAPIES

EHA Library, Hans Michael KVASNICKA, 215064

WHO 2016 CLASSIFICATION IN 80 CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Michelina SANTOPIETRO, 215065

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW-RISK MYELOFIBROSIS (MF) IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 215066

PRIMARY THERAPY AND SURVIVAL IN PRIMARY MYELOFIBROSIS: A NATIONWIDE POPULATION-BASED ANALYSIS AMONG 1,445 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 2001 AND 2015

EHA Library, Avinash Dinmohamed, 215067

RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR POLYCYTHAEMIA VERA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR-LED RANDOMISED TRIAL

EHA Library, Claire Harrison, 215068

RESULTS FROM ONGOING PHASE 1/2 TRIAL OF SL-401 IN PATIENTS WITH RELAPSED/REFRACTORY CMML

EHA Library, Mrinal Patnaik, 215069

DABRAFENIB IN PEDIATRIC PATIENTS WITH BRAF V600–POSITIVE LANGERHANS CELL HISTIOCYTOSIS

EHA Library, Darren Hargrave, 215070